Tentt

Marvel Biosciences Gets $600K Alberta Innovates Funding

Announced
HealthcareOther

Deal Overview

Marvel Biosciences Corp. secured non-dilutive funding from the Alberta Innovates CarE (AICE) market access program to support Phase I testing of its lead compound, MB-204. The AICE-funded project is worth $600,000 and is intended to offset a significant portion of the overall Phase I clinical trial cost.

The company said the AICE program is highly competitive and peer-reviewed, providing third-party validation for MB-204’s scientific and commercial potential. Marvel also referenced a separate grant from Canada’s NRC IRAP for development of a novel small-volume, liquid-based formulation designed to be pediatric-friendly and improve compliance for patients who have difficulty swallowing.

Key Details

Target
Marvel Biosciences
Deal Size
Under $10M
Reported Value
$600,000

Filed under

Source

Read full article on globenewswire.com

via GlobeNewswire — Financing · March 30, 2026

Powered by Tentt

Source healthcare deals for your firm

Tentt builds and operates managed deal origination services for PE firms, M&A advisors, and commercial lenders. We map the target universe, monitor signals, and execute outreach — white-labelled to your firm.

Book a 30-min intro call

Related Deals

See all Healthcare deals →